AI Article Synopsis

  • A successful tuberculosis (TB) vaccine requires low genomic diversity in Mycobacterium tuberculosis strains and strong T-cell responses across diverse human populations, which can be assessed through in silico MHC-peptide binding predictions.* -
  • The study focused on the candidate TB vaccine antigens Mtb72F and M72, which are recombinant proteins from Mtb32A and Mtb39A, and demonstrated their efficacy in eliciting CD4(+) T-cell responses in various global populations.* -
  • Sequence analyses showed high conservation (≥98% identity) among TB strains for the vaccine proteins, with numerous predicted MHC class II and class I-binding peptides indicating the vaccines' potential across different human genetic backgrounds.*

Article Abstract

Background: Requisites for an efficacious tuberculosis (TB) vaccine are a minimal genomic diversity among infectious Mycobacterium tuberculosis strains for the selected antigen, and the capability to induce robust T-cell responses in the majority of human populations. A tool in the identification of putative T-cell epitopes is in silico prediction of major histocompatibility complex (MHC)-peptide binding. Candidate TB vaccine antigen Mtb72F and its successor M72 are recombinant fusion proteins derived from Mtb32A and Mtb39A (encoded by Rv0125 and Rv1196, respectively). Adjuvanted Mtb72F and M72 candidate vaccines were shown to induce CD4(+) T-cell responses in European, US, African and Asian populations.

Methods: Sequence conservation of Mtb32A, Mtb39A, Mtb72F and M72 among 46 strains (prevalent Mycobacterium strains causing human TB disease, and H37Ra) was assessed by multiple alignments using ClustalX. For Mtb32A, Mtb39A and Mtb72F, 15-mer human leukocyte antigen (HLA)-class II-binding peptides were predicted for 158 DRB1 alleles prevailing in populations with high TB burden, 6 DRB3/4/5, 8 DQ and 6 DP alleles, using NetMHCII-pan-3.0. Results for 3 DRB1 alleles were compared with previously published allele-matched in vitro binding data. Additional analyses were done for M72. Nonameric MHC class I-binding peptides in Mtb72F were predicted for three alleles representative of class I supertypes A02, A03 and B07, using seven prediction algorithms.

Results: Sequence identity among strains was ≥98 % for each protein. Residue changes in Mtb39A comprised primarily single residue or nucleotide insertions and/or deletions in repeat regions, and were observed in 67 % of strains. For Mtb72F, 156 DRB1, 6 DRB3/4/5, 7 DQ and 5 DP alleles were predicted to contain at least one MHC class II-binding peptide, and class I-binding peptides were predicted for each HLA-A/B allele. Comparison of predicted MHC-II-binding peptides with experimental data indicated that the algorithm's sensitivity and specificity were variable among alleles.

Conclusions: The sequences from which Mtb72F and M72 are derived are highly conserved among representative Mycobacterium strains. Predicted putative T-cell epitopes in M72 and/or Mtb72F covered a wide array of HLA alleles. In silico binding predictions for class I- and II-binding putative epitopes can be complemented with biochemical verification of HLA binding capacity, processing and immunogenicity of the predicted peptides.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619029PMC
http://dx.doi.org/10.1186/s12865-015-0119-7DOI Listing

Publication Analysis

Top Keywords

mtb72f m72
16
mtb32a mtb39a
12
mtb72f
9
sequence conservation
8
human leukocyte
8
binding predictions
8
candidate vaccine
8
t-cell responses
8
putative t-cell
8
t-cell epitopes
8

Similar Publications

Article Synopsis
  • A successful tuberculosis (TB) vaccine requires low genomic diversity in Mycobacterium tuberculosis strains and strong T-cell responses across diverse human populations, which can be assessed through in silico MHC-peptide binding predictions.* -
  • The study focused on the candidate TB vaccine antigens Mtb72F and M72, which are recombinant proteins from Mtb32A and Mtb39A, and demonstrated their efficacy in eliciting CD4(+) T-cell responses in various global populations.* -
  • Sequence analyses showed high conservation (≥98% identity) among TB strains for the vaccine proteins, with numerous predicted MHC class II and class I-binding peptides indicating the vaccines' potential across different human genetic backgrounds.*
View Article and Find Full Text PDF

Background: The Bacille Calmette-Guérin (BCG) tuberculosis (TB) vaccine provides incomplete protection, necessitating development of an effective vaccine against TB disease. The Mtb72F/AS02 candidate vaccine was previously shown to be clinically well tolerated and immunogenic in Purified Protein Derivative (PPD)-negative adults. To improve the stability of Mtb72F, a point mutation was introduced into a putative serine protease site to give the final M72 construct.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!